JASPER THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | $41.6M | $34.3M | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $63.1M | $55.8M | $51.8M | $34.6M | $25.4M | $15.9M |
| SG&A Expense | — | $20.8M | $20.4M | $17.1M | $16.6M | $11.4M | $4.8M |
| Operating Income | — | $-83.9M | $-76.2M | $-68.9M | $-51.2M | $-36.8M | $-20.7M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | $-6.4M |
| Income Tax Expense | — | — | $2.0K | $2.0K | — | — | $38.5K |
| Net Income | — | $-75.8M | $-71.3M | $-64.5M | $-37.7M | $-30.6M | $-31.7M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-3.95 | $-4.89 | $-6.18 | $-3.44 | $-0.90 | $-1.72 |
| EPS (Diluted) | — | $-3.95 | $-4.89 | $-6.18 | $-3.44 | $-0.90 | $-1.72 |
| Shares Outstanding (Basic) | 28.0M | 19.2M | 14.6M | 10.4M | 10.9M | 34.2M | 8.3M |
| Shares Outstanding (Diluted) | 28.0M | 19.2M | 14.6M | 10.4M | 10.9M | 34.2M | 8.3M |
| Dividends Per Share | — | — | — | — | — | — | — |